Argos Therapeutics to Participate in 2016 BIO Investor Forum
October 14 2016 - 8:00AM
Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology
company focused on the development and commercialization of
individualized immunotherapies based on the
Arcelis® technology platform, today announced that
the company will be presenting at the 2016 BIO Investor Forum to be
held October 18-19 at the Westin St. Francis Hotel in San
Francisco, California.
Richard Katz, MD, chief financial officer of Argos,
will present on Wednesday, October 19 at 11:30am PT in the
Elizabethan C presentation room.
The BIO Investor Forum is an international biotech
investor conference focused on early and established private
companies as well as emerging public companies. The event features
plenary sessions, business roundtables and therapeutic workshops,
company presentations, and one-on-one partnering meetings. For more
information, visit
https://www.bio.org/events/bio-investor-forum.
About the Arcelis® Technology
PlatformArcelis® is a precision
immunotherapy technology that captures both mutated and variant
antigens that are specific to each patient’s individual disease. It
is designed to overcome immunosuppression by producing a
specifically targeted, durable memory T-cell response without
adjuvants that may be associated with toxicity. The technology is
potentially applicable to the treatment of a wide range of
different cancers and infectious diseases, and is designed to
overcome many of the manufacturing and commercialization challenges
that have impeded other personalized immunotherapies. The
Arcelis® process uses only a small disease sample
or biopsy as the source of disease-specific antigens, and the
patient’s own dendritic cells, which are optimized from cells
collected by a single leukapheresis procedure. The proprietary
process uses RNA isolated from the patient's disease sample to
program dendritic cells to target disease-specific antigens. These
activated, antigen-loaded dendritic cells are then formulated with
the patient’s plasma, and administered via intradermal injection as
an individualized immunotherapy.
About Argos TherapeuticsArgos
Therapeutics is an immuno-oncology company focused on the
development and commercialization of individualized immunotherapies
for the treatment of cancer and infectious diseases using its
Arcelis® technology platform. Argos' most advanced
product candidate, AGS-003, is being evaluated in
the pivotal ADAPT Phase 3 clinical trial for the
treatment of metastatic renal cell carcinoma (mRCC). In
addition, AGS-003 is being studied in
Phase 2 investigator-initiated clinical trials as
neoadjuvant therapy for renal cell carcinoma (RCC) and for the
treatment of non-small cell lung cancer (NSCLC). Argos is also
developing a separate Arcelis®-based product
candidate, AGS-004, for the treatment of human
immunodeficiency virus (HIV), which is currently being evaluated in
an investigator-initiated Phase 2 clinical trial
aimed at HIV eradication in adult patients.
Forward Looking StatementsAny
statements in this press release about Argos’ future expectations,
plans and prospects, including statements about the expected and
potential future closings of the private placement, Argos’
financial prospects, anticipated use of proceeds, future operations
and sufficiency of funds for future operations, clinical
development of Argos’ product candidates, expectations regarding
future clinical trials and future expectations and plans and
prospects for Argos and other statements containing the words
"believes," "anticipates," "estimates," "expects," "intends,"
"plans," "predicts," "projects," "targets," “may,” "potential,"
"will," "would," "could," "should," "continue," and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including whether Argos' cash resources will be
sufficient to fund its continuing operations for the periods
anticipated; whether results obtained in clinical trials will be
indicative of results obtained in future clinical trials; whether
Argos' product candidates will advance through the clinical trial
process on a timely basis; whether the results of such trials will
warrant submission for approval from the United States Food and
Drug Administration or equivalent foreign regulatory
agencies; whether Argos' product candidates will receive
approval from regulatory agencies on a timely basis or at all;
whether, if product candidates obtain approval, they will be
successfully distributed and marketed; and other factors discussed
in the "Risk Factors" section of Argos’ Form 10-Q for the quarter
ended June 30, 2016, which is on file with the SEC, and in other
filings Argos makes with the SEC from time to time. In addition,
the forward-looking statements included in this press release
represent Argos’ views as of the date hereof. Argos anticipates
that subsequent events and developments will cause Argos’ views to
change. However, while Argos may elect to update these
forward-looking statements at some point in the future, Argos
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Argos’ views as of any date subsequent to the date
hereof.
Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
Investor contact:
John Menditto
Argos Therapeutics, Inc.
919-908-0687
jmenditto@argostherapeutics.com